PCSK9 inhibitors medication

Aug 07, 2026

Summary For nearly a decade, PCSK9 inhibitors have been highly effective at lowering LDL cholesterol, but their growth has been limited by the need for injections. The U.S. FDA approval of Merck’s LIPFENDRA (enlicitide) changes that by introducing the first oral PCSK9 inhibitor, marking a major shift from ne...

Sep 08, 2025

The Unmet Need in Cholesterol Management Cardiovascular Diseases (CVDs) continue to be one of the leading causes of morbidity and mortality worldwide, primarily driven by underlying lipid disorders, including Hypercholesterolemia (familial and non-familial hypercholesterolemia), Dyslipidemia, Atherosclerotic Car...

Oct 10, 2022

Proprotein convertase subtilisin/Kexin type 9 (PCSK9) affects LDL receptor degradation and decreases the clearance of circulating LDL particles, which is crucial in cholesterol metabolism. PCSK9 is predominantly generated by hepatocytes, with additional sources including the intestines and kidneys. PCSK9 reduces LD...